Running head: Long COVID-19 and cognition

Long COVID neuropsychological deficits after severe, moderate or mild infection

- P. Voruz<sup>1,2,3</sup>, G. Allali<sup>2,3</sup>, L. Benzakour<sup>3,4</sup>, A. Nuber-Champier<sup>1</sup>, M. Thomasson<sup>1,2</sup>, I. Jacot<sup>1,2</sup>, 6
- J. Pierce<sup>1</sup>, P. Lalive<sup>2,3</sup>, K-O. Lövblad<sup>3,5</sup>, O. Braillard<sup>6</sup>, M. Coen<sup>3,7</sup>, J. Serratrice<sup>3,7</sup>, J. Pugin<sup>3,8</sup>, 7
- R. Ptak<sup>3,9</sup>, I. Guessous<sup>3,6</sup>, B.N. Landis<sup>3,10</sup>, F. Assal<sup>2,3#</sup> & J.A. Péron<sup>1,2#\*</sup> 8
- 10 # These authors contributed equally to this work
- 12 **Affiliations:**

1

2

3

4

5

9

11

26

- 13 <sup>1</sup> Clinical and Experimental Neuropsychology Laboratory, Faculty of Psychology, University
- of Geneva, Geneva, Switzerland 14
- 15 <sup>2</sup> Neurology Department, Geneva University Hospitals, Switzerland
- 16 <sup>3</sup> Faculty of Medicine, University of Geneva, Switzerland
- 17 <sup>4</sup> Psychiatry Department, Geneva University Hospitals, Switzerland
- <sup>5</sup> Diagnostic and Interventional Neuroradiology Department, Geneva University Hospitals, 18
- 19 Switzerland
- <sup>6</sup> Division and Department of Primary Care, Geneva University Hospitals, Switzerland 20
- 21 <sup>7</sup> Internal Medicine Department, Geneva University Hospitals, Switzerland
- <sup>8</sup> Intensive Care Department, Geneva University Hospitals, Switzerland 22
- 23 <sup>9</sup> Neurorehabilitation Department, Geneva University Hospital, Switzerland
- Rhinology-Olfactology Unit, Otorhinolaryngology Department, Geneva University 24
- Hospitals, Switzerland 25
- 27 \*Corresponding author:
- Dre Julie Péron, Faculté de Psychologie et des Sciences de l'Education, 40 bd du Pont d'Arve, 28
- 1205 Geneva, Switzerland, Tel.: +41 22 379 94 55 29
- 30 julie.peron@unige.ch

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

**ABSTRACT Background:** There is growing awareness that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can include long-term neuropsychological deficits, even in its mild or moderate respiratory forms. **Methods:** Standardized neuropsychological, psychiatric, neurological and olfactory tests were administered to 45 patients (categorized according to the severity of their respiratory symptoms during the acute phase)  $236.51 \pm 22.54$  days post-discharge following SARS-CoV-2 infection. **Results:** Deficits were found in all the domains of cognition and the prevalence of psychiatric symptoms was also high in the three groups. The severe performed more poorly on long-term episodic memory and exhibited greater anosognosia. The moderate had poorer emotion recognition, which was positively correlated with persistent olfactory dysfunction. The mild were more stressed, anxious and depressed. **Conclusion:** The data support the hypothesis that the virus targets the central nervous system (and notably the limbic system), and support the notion of different neuropsychological phenotypes.

perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

Voruz et al. - Long COVID-19 and cognition

### INTRODUCTION

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

The presence of long-term neuropsychological deficits following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is strongly suspected, even in its mild or moderate forms. This is based on four main arguments. First, longitudinal studies of SARS-CoV and the Middle East respiratory syndrome, which share many pathogenetic similarities with SARS-CoV-2, have demonstrated the presence of sleep disorders, frequent recall of traumatic memories, emotional lability, impaired concentration, fatigue, and impaired memory in more than 15% of affected patients 1 month to 3.5 years following infection (Rogers et al., 2020). Second, neurological and cognitive symptoms observed in 38.6% of patients in the acute phase (Mao et al., 2020) are hypothesized to have similar pathophysiological causes to those responsible for short- and long-term cognitive impairment in other pathologies. Neuropsychological studies among patients with neuro-immunological diseases such as HIV (Wendelken & Valcour, 2012), multiple sclerosis (Piras et al., 2003), and encephalitis (van Sonderen et al., 2016), have reported specific long-term deficits in cognitive functions (e.g., memory, executive or emotional processes) with a neuro-infectious and neuro-immunological pathogenesis. Furthermore, increased prevalence of stroke has been reported in patients with COVID-19 (Merkler et al., 2020; Nannoni, de Groot, Bell, & Markus, 2020), leading to additional short- and long-term neurological and cognitive deficits, depending on the location of the lesion, as described for example by Oxley et al. (2020), who examined five patients aged under 50 years with large-vessel stroke. *Third*, sudden-onset anosmia is a symptom that has been described extremely frequently by patients following infection with SARS-CoV-2, regardless of the severity of their respiratory symptoms (De Maria, Varese, Dentone, Barisione, & Bassetti, 2020; Lee & Lee, 2020). Researchers have identified sustentacular cells as the potential entry point into the

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

olfactory epithelium (Brann et al., 2020). Unlike olfactory neurons, these cells carry ACE2 receptors (Fodoulian et al., 2020). However, the exact extent to which the olfactory epithelium is affected is still unclear, so it is currently impossible to predict which patients with COVID-19 will develop long-term olfactory disorders (Butowt & Bilinska, 2020). It is not known if and how olfactory neurons are affected by disruption of sustentacular cell function. It is also unclear whether the SARS-CoV-2 infection is confined solely to the olfactory epithelium (Vaira et al., 2020), or whether it follows a neuroinvasive pathway via the cribriform plate. Based on other neuro-olfactory pathologies, it has been suggested that entry through the nose-brain barrier is likely and probably underestimated (Doty, 2008; Landis, Vodicka, & Hummel, 2010). Some authors suggest that the olfactory bulb is damaged following COVID-19 infection (Kandemirli, Altundag, Yildirim, Sanli, & Saatci, 2021; Meinhardt et al., 2021). Interestingly, an <sup>18</sup>F-FDG PET study among patients with SARS-CoV-2 and anosmia highlighted hypometabolism specifically in the neural substrates of the olfactory circuit, which could indicate an attack on the central nervous system (CNS) (pre-/postcentral gyrus, thalamus/hypothalamus, cerebellum and brainstem) via the olfactory pathway (Guedj et al., 2021; Guedj et al., 2020). Fourth, to our knowledge only one study has so far explored the short-term impact (10-40 days post-hospital discharge) of SARS-CoV-2 infection on cognition using a validated and standardized methodology with face-to-face interviews (Almeria, Cejudo, Sotoca, Deus, & Krupinski, 2020). These authors reported short-term disruption of memory, attention, and executive functions. Unfortunately, they did not explore the impact of the severity of the respiratory symptoms. Hampshire et al. (2020) did consider the influence of severity in their study, but only found a trend toward significance, and used online tests that had not been psychometrically validated. Woo et al. (2020) also addressed the short-term (20-105 days post-infection) impact of SARS-CoV-2 in mild or moderate patients, by administering the

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

Modified Telephone Interview for Cognitive Status, a screening battery that was initially developed for the early detection of dementia. They reported memory and attentional deficits in patients compared with matched controls. These approaches had several potential methodological issues, such as the use of an online survey relying on participants' unverified self-reports (Hampshire et al., 2020), and the failure to collect information about patients' clinical history or medical antecedents (Almeria et al., 2020; Woo et al., 2020), which may have induced interindividual variability in the results. Moreover, no study has investigated the long-term effects of infection on the instrumental domains (including visuospatial processing, ideomotor praxis, and language) or emotion recognition. Finally, to our knowledge, the impact of psychiatric factors on the cognitive functioning of patients with SARS-CoV-2 has not been studied thus far. Epidemiological studies have highlighted the impact of the pandemic and related health measures such as lockdown on mental health (Bäuerle et al., 2020; Röhr et al., 2020; Salari et al., 2020), with increased anxiety and depressive symptoms (Wang et al., 2020) within the general population. Being infected by SARS-CoV-2 also has a major affective impact (Almeria et al., 2020). Long-term psychiatric consequences of COVID-19 described so far include anxiety, depressive symptoms, insomnia, and posttraumatic stress disorder (PTSD) (Mazza et al., 2020), especially among patients with a history of psychiatric illness or who required intensive care. All these symptoms may arise from a neurobiological disturbance and the ensuing neuroinflammation process (Kohler, Krogh, Mors, & Eriksen Benros, 2016). In this context, the present study had three main objectives; i) investigate whether SARS-COV-2 causes long-term (6-9 months after the acute phase) neuropsychological deficits, identify the nature of the affected cognitive and psychiatric domains, and determine their impact on quality of life; ii) explore whether cognitive and psychiatric symptoms are a function of the severity of the respiratory symptoms in the acute phase, and whether patients

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

who present with moderate or even mild forms also exhibit cognitive dysfunctions and/or psychiatric symptoms; and iii) look for correlations between long-term neuropsychological deficits and psychiatric symptoms resulting from a neurobiological disturbance caused by SARS-CoV-2 and/or personal stressful experience in the context of the global health crisis, but also between these deficits and olfactory functions. To this end, patients underwent a comprehensive neuropsychological assessment probing multiple cognitive domains, emotion recognition, psychiatric symptoms, and olfaction. They were divided into three groups according to the respiratory severity of the disease in the acute phase: severe (intensive care with respiratory assistance), moderate (hospitalized without respiratory assistance), or mild (not hospitalized). Corresponding with our three objectives, we developed three hypotheses. First, we hypothesized that SARS-CoV-2 causes long-term neuropsychological deficits that continue to affect patients' functioning and quality of life 6-9 months post-infection. We expected to observe cognitive deficits in memory, executive function and logical reasoning (Almeria et al., 2020), as well as the emergence of psychiatric disorders such as anxiety, depressive symptoms, insomnia, and PTSD (Troyer, Kohn, & Hong, 2020; Varatharaj et al., 2020). Second, we hypothesized that the presence of neuropsychological deficits is positively correlated with disease severity in the acute phase (Hampshire et al., 2020). Third, although ours was an exploratory study, we hypothesized that pandemic- and disease-related psychiatric symptoms explain a significant proportion (but not all) of the variance observed for neuropsychological measures (Baig, Khaleeq, Ali, & Syeda, 2020). Based on Soudry, Lemogne, Malinvaud, Consoli, and Bonfils (2011) and Guedj et al. (2021), we also predicted that a long-term reduction in olfactory performance would correlate positively with any impaired performance on memory and emotion recognition, owing to common neuronal substrates.

### **METHODS**

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

### Participants (see Table 1)

Three groups of patients who had been infected with SARS-CoV-2 were included in the study: 15 patients who had been admitted to intensive care during the acute phase of the infection (severe); 15 patients who had been hospitalized but did not require intensive care (moderate); and 15 patients who had tested positive but had not been hospitalized. All the patients had had their infection confirmed by positive polymerase chain reaction (PCR) from nasopharyngeal swab and/or positive serology. On average, the moderate patients had been hospitalized for 9.27 days ( $\pm$  9.52), and the severe patients for 37.40 days ( $\pm$  30.50). In comparison with other studies on SARS-CoV-2, the mean duration of hospitalization for the moderate group was somewhat longer, but this was driven by a single patient. The median number of days for this group was 7, which is comparable to that observed in other studies in Switzerland (Regina et al., 2020). The required number of participants in each group was determined by a power analysis involving the comparison of two means:  $N = \frac{2 \times \sigma^2 (z_{\underline{\alpha}} + z_{\beta})}{(\bar{X}_1 - \bar{X}_2)^2}$ . This analysis was based on the literature evaluating the short-term neuropsychological effects of SARS-CoV-2 on mild patients (Woo et al., 2020). To achieve the desired statistical power  $(1 - \beta)$  of 90% and risk of Type I error ( $\alpha$ ) of 0.05, results indicated that for a one-sided hypothesis, 13 participants were needed in each group. As we planned to perform nonparametric analyses, we had to increase the sample size by 15% (Lehmann, 2012), resulting in 15 participants per group. The three groups were matched for median age (mild = 57 years; moderate = 55 years; severe = 59 years), sociocultural level, and clinical variables. Given the risk factors associated with the severe form of SARS-CoV-2, there were significantly higher proportions of men

172

173

174

175

176

177

178

179

180

(severe = 86.66%; moderate = 40%; mild = 46.66%) and patients with diabetes. Participants were recruited via admission lists provided by the treating doctors at Geneva University Hospitals: LB and OB. For each patient, we carried out a medical file review, followed by a telephone call inviting the patient to take part in the study, if all the eligibility criteria were met. Exclusion criteria were a history of neurological issues, psychiatric disorders (two of the included participants had had an episode of depression more than 10 years before their SARS-CoV-2 infection), cancer (to exclude possible chemotherapy- and radiotherapy-related cognitive impairment (Cascella et al., 2018)), neuro-developmental pathologies, pregnancy, and age above 80 years.

### Table 1: Sociodemographic data and relevant medical antecedents

	Mild	Moderate	Severe	<b>p</b> value
	n = 15	<i>n</i> = 15	<i>n</i> = 15	
Age in years (mean $\pm SD$ )	53.33 (± 8.93)	55.87 (± 11.45)	61.80 (± 10.42)	ns
Education level in years (mean $\pm SD$ )	2.67 (± 0.49)	2.53 (± 0.74)	2.40 (± 0.63)	ns
Gender (F/M)	8/7	9/6	2/13	.021
Days of hospitalization (mean $\pm SD$ )	-	9.27 (± 9.52)	37.40 (± 30.50)	-
Diabetes	0/15	2/15	5/15	.041
Smoking	2/15	0/15	1/15	.351
History of respiratory disorders	3/15	3/15	5/15	.625
History of cardiovascular disorders	3/15	2/15	4/15	.605
History of neurological disorders	0/15	0/15	0/15	1
History of psychiatric disorders	1/15	0/15	1/15	.351
History of cancer	0/15	0/15	0/15	1
History of severe immunosuppression	0/15	0/15	0/15	1
History of developmental disorders	0/15	0/15	0/15	1
Chronic renal failure	0/15	0/15	2/15	129
Sleep apnea syndrome	1/15	1/15	3/15	.071

Note. F: female; M: male; ns: not significant; SD: standard deviation. 

### General procedure and ethics

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

A flowchart displaying the successive stages of the study according to the eligibility criteria for each experimental group is provided in Figure 1.

After being given a complete description of the study, participants provided their written informed consent. The study was conducted in accordance with the Declaration of Helsinki, and the study protocol was approved by the cantonal ethics committee of Geneva (CER-02186).




Figure 1: Flowchart of the study

### **Neuropsychological assessment**

A comprehensive neuropsychological battery was administered to participants 6-9 months after their positive PCR test (236.51  $\pm$  22.54 days). This battery included a series of tests and questionnaires assessing most of the domains of cognition, emotion recognition, fatigue, and quality of life (see below). The tests were administered by clinical psychologists (mean

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

duration: approx. 180 minutes), and the questionnaires were administered online via Qualtrics software (Qualtrics, Provo, UT) (mean duration: approx. 60 minutes). Executive functions. Several tasks were administered to evaluate three executive functions (i.e., inhibition, shifting and updating), in accordance with Miyake et al. (2000): Stroop task, Trail Making Test, and categorical and lexical verbal fluency from the GREFEX battery (Roussel & Godefroy, 2008). Verbal and visuospatial working memory were assessed using the backward digit span (Drozdick, Raiford, Wahlstrom, & Weiss, 2018) and backward Corsi test (Kessels, Van Zandvoort, Postma, Kappelle, & De Haan, 2000). We also administered computer-based tasks designed to gauge focused attention, divided attention, phasic alertness, working memory, and incompatibility using version 2.1 of the Test for Attentional Performance (TAP) (Zimmermann & Fimm, 2007). Memory systems. The short-term memory system was assessed with forward digit spans (Drozdick et al., 2018) and the Corsi test (Kessels et al., 2000). Verbal episodic memory was assessed with the 16-item Grober and Buschke free/cued recall (RL/RI 16) paradigm (Grober & Buschke, 1987), as it distinguishes between the cognitive subprocesses of encoding, storage, and recall (Van der Linden et al., 2004). Visual episodic memory was assessed with the delayed recall of the Rey-Osterrieth Complex Figure test (Meyers & Meyers, 1995). Instrumental function. Language was assessed with the BECLA battery (Macoir, Gauthier, Jean, & Potvin, 2016), ideomotor praxis with a short validated battery (Mahieux-Laurent et al., 2009), visuoconstructive abilities with the Rey-Osterrieth Complex Figure test (Meyers & Meyers, 1995), and visuoperceptual functions with 4 subtests from the Visual Object and Space Perception battery (VOSP) (Warrington & James, 1991) measuring object perception (fragmented letters, object decision) and spatial perception (localization of numbers, analysis of cubes).

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

Logical reasoning. This was assessed using the Puzzle and Matrices subtests of the Wechsler Adult Intelligence Scale–Fourth Edition (WAIS-4) (Wechsler, 2008). Emotion. Multimodal emotion recognition was assessed with the Geneva Emotion Recognition Test (GERT) (Schlegel, Grandjean, & Scherer, 2014). In this emotion recognition task, participants watched 42 video clips, in which 10 actors displayed 14 different emotions (pride, fun, joy, pleasure, relief, interest, anger, irritation, fear, anxiety, disgust, despair, sadness, surprise) while expressing nonverbal content. After each clip, participants were asked to choose one emotion from the list of 14 that best described the emotion played by the actor. Anosognosia and cognitive complaints. We administered the Cognitive Complaints Questionnaire (QPC) (Thomas-Antérion, Ribas, Honoré-Masson, Million, & Laurent, 2004) and the Behavior Rating Inventory of Executive Function-adult Version (BRIEF-A) (Roth, Gioia, & Isquith, 2005). To quantify anosognosia, we calculated a self-appraisal discrepancy (SAD) score for each memory and executive domain evaluated by the QPC and BRIEF-A (Leicht, Berwig, & Gertz, 2010; Rosen et al., 2010; Tondelli et al., 2018). First, we calculated standardized scores for the cognitive complaints, dividing the raw scores of the self-report questionnaires into four categories: 0 = normal behavior; 1 = limited influence on daily life; 2 = noticeable influence on daily life; and 3 = substantial influence on daily life. Then, each standardized score yielded by one of these self-administered questionnaires of cognitive complaints was subtracted from the standardized score for the relevant function. For example, if a patient reported no memory disorders (QPC score = 3) but performed very poorly on Grober and Buschke (RL/RI 16) – delayed free recall (score = 0), he/she would exhibit anosognosia for memory dysfunction: 0 (standardized score on episodic memory test) -3(score on self-questionnaire of memory complaints) = -3. SAD scores could therefore range from -3 to 3, and any score below 0 indicated anosognosia.

### Other clinical outcomes

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

We collected patients' sociodemographic data and medical history. Psychiatric data (including those concerning current fatigue, insomnia, and somnolence), olfactory abilities, and quality of life at the time of the interview were also collected. Finally, a neurological assessment of CNS and peripheral nervous system functions and walking was carried out by two certified neurologists (FA and GA). Sociodemographic and clinical data. In addition to age, collected during the inclusion interview, we recorded patients' gender, handedness, and education level. To complement information about previous neurological, psychiatric, and developmental conditions and cancer collected during the inclusion interview, we asked patients about previous cardiovascular disease, respiratory disorders, immunosuppression status, sleep apnea syndrome, diabetes, and smoking. Participants were asked to describe the symptoms they had experienced both during the acute phase of infection and currently (6-9 months postinfection), and the number of days they had spent in hospital, where relevant. Psychiatric data. Depression was assessed with the Beck Depression Inventory-Second edition (BDI-II) (Beck, Steer, & Brown, 1996), anxiety with the State-Trait Anxiety Inventory (STAI-S and STAI-T) (Spielberger, Gorsuch, Lushene, Vagg, & Jacobs, 1993), apathy and its distinct subtypes with the Apathy Motivation Index (AMI) (Ang, Lockwood, Apps, Muhammed, & Husain, 2017), PTSD with the Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5) (Ashbaugh, Houle-Johnson, Herbert, El-Hage, & Brunet, 2016), manic symptoms with the Goldberg Mania Inventory (Goldberg, 1993), dissociative symptoms in the patient's daily life with the Dissociative Experience Scale (DES) (Carlson & Putnam, 1986), current stress perception with the Perceived Stress Scale – 14 items (PSS-14) (Lesage, Berjot, & Deschamps, 2012), cognitive reappraisal of an emotional episode and expressive emotional suppression capacities with the Emotion Regulation Questionnaire (ERQ) (Gross &

275

276

277

278

279

280

281

282

283

284

285

286

287

288

John, 2003) and susceptibility to others' emotions with the Emotion Contagion Scale (ECS) (Doherty, 1997). Finally, fatigue was assessed with the French version of the Fatigue Impact Scale (Debouverie, Pittion-Vouyovitch, Louis, & Guillemin, 2007), potential sleeping disorders with the Insomnia Severity Index (ISI) (Morin, 1993), and symptoms of sleepiness in daily life with the Epworth Sleepiness Scale (Johns, 1991). Olfaction. Olfactory performance was measured with the Sniffin' Sticks test battery. This test consists of commercially available pens with 16 common odors, which were each presented for 2 s in front of both nostrils. For each odor, patients had to choose between four descriptors in a multiple-choice task. Participants' scores ranged from 0 to 16. Based on Kobal et al. (2000), we set three thresholds. Patients with an identification score of 0-7 were considered anosmic, 8-12 hyposmic, and 12-16 normosmic. Quality of life. We administered the SF-36 (Bousquet et al., 1994), which distinguishes between the physical and mental aspects of quality of life.

### **Statistical analyses**

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

Prevalence of neuropsychological deficits and psychiatric symptoms (Objective 1) For each neuropsychological test, we first compared patients' performances with normative data for the validated neuropsychological tools. As the standardization depended upon the distribution of the normative data collected from the reference sample (t and z scores, percentiles, or standard scores), the comparative tests were adjusted according to the guidelines provided by the authors of the validation study for each test. Second, the data were normalized according to the guidelines of the Swiss Association of Neuropsychology (Frei et al., 2016; Heaton, Grant, & Matthews, 1991), making it possible to classify the standardized as follows: far below the norm (< 2<sup>nd</sup> percentile), substandard (2<sup>nd</sup>-5<sup>th</sup> percentiles), borderline or below the normal limit ( $6^{th}$ - $15^{th}$  percentiles), normal ( $\geq 16^{th}$  percentile). This standardization allowed us to quantify the prevalence of each type of disorder, while controlling for variables such as age, education level, and gender. To consider the possible effect of fatigue and increase the robustness of the results, only those performances that were far below the norm (< 2<sup>nd</sup> percentile) or substandard (2<sup>nd</sup>-5<sup>th</sup> percentile) were used to calculate the prevalence of neuropsychological deficits. Results that were just below the norm were therefore not considered in the prevalence table.

*Neuropsychological deficits as a function of disease severity (Objective 2)* For each neuropsychological, psychiatric or quality-of-life measure, we compared the three groups (severe, moderate, and mild) on the raw data. Given the distribution of the samples, we used nonparametric Kruskal-Wallis tests. For significant (p < .05) measures, Mann-Whitney tests were performed for the 2 x 2 comparisons with Bonferroni-corrected p values.

313

314

315

316

317

318

319

320

321

322

323

324

325

Relationships between neuropsychological deficits, psychiatric symptoms, and other secondary variables (Objective 3) For each neuropsychological variable of interest, forward stepwise multiple regression analyses were performed on the raw cognitive data with the significant sociodemographic variables, sniff test results and psychiatric measures, to quantify relationships between these variables and the neuropsychological functions. In parallel, and in order to elucidate the cognitive data's underlying structure, we performed a principal component analysis (PCA) on the raw test and questionnaire scores assessing cognition and emotion recognition. The list of variables included in the PCA is available in Supplementary Information 1. We extracted the first three components with the highest eigenvalues. We then reran forward stepwise multiple regressions for each cognitive component, with the same variables of interest as those described above.

Neuropsychological, psychiatric and olfactory profiles 6-9 months post-

Voruz et al. - Long COVID-19 and cognition

### **RESULTS**

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

infection The first aim of this study was to assess the prevalence of neuropsychological impairments and psychiatric symptoms 6-9 months after SARS-CoV-2 infection. We compared patients' performances with available normative data to identify the number of impaired scores per patient, group, and test. The prevalence of cognitive impairments in each group 236.51  $\pm$ 22.54 days after infection is set out in Table 2, and the prevalence of psychiatric symptoms in Table 3 Cognition. Cognitive deficits common to all three groups were observed in the following domains: long-term episodic memory in both the verbal and visual modalities, executive functions (e.g., inhibition and mental flexibility, and both categorical and literal verbal fluency), sustained and divided attention, and language (semantic matching and naming). All three groups exhibited anosognosia for executive dysfunction (see Table 2) Psychiatric disorders. All three groups displayed anxiety, mania, the social component of apathy, stress, PTSD, and dissociative disorders. All three groups also reported insomnia, fatigue and pathological somnolence (see Table 3). The only psychiatric variable where the prevalence score stood out for severe patients was emotional apathy, as measured with AMI (see Table 3). Olfaction. 33.33% of the mild group, 73.33% of the moderate group, and 46.66% of the severe group displayed hyposmia. There was no anosmia in the mild and moderate groups, but 13.33% of the severe group were anosmic (see Table 3).

Table 2: Cognitive deficits among patients with mild, moderate or severe COVID-19 6-9 months post-infection

		Mild $(n = 15)$	Moderate $(n = 15)$	Severe $(n = 15)$	p value
		Prevalence (%)	Prevalence (%)	Prevalence (%)	
Memory					
Verbal episodic memory	Grober & Buschke (RL/RI 16) - Immediate recall	0.00	0.00	6.67	.066
	Grober & Buschke (RL/RI 16) – Sum of 3 free recalls	0.00	0.00	0.00	.110
	Grober & Buschke (RL/RI 16) – Sum of 3 total recalls	0.00	13.33	6.67	.229
	Grober & Buschke (RL/RI 16) - Delayed free recall	0.00	6.67	6.67	.005
	Grober & Buschke (RL/RI 16) - Delayed total recall	6.67	13.33	20.00	.450
Visuospatial episodic memory	Rey Figure - Copy time	0.00	0.00	0.00	.459
	Rey Figure - Score	6.67	20.00	6.67	.904
	Rey Figure - Immediate recall (3')	0.00	26.67	0.00	.117
	Rey Figure - Delayed recall (20')	0.00	13.33	0.00	.046
Verbal short-term memory	MEM III -Spans	0.00	6.67	6.67	.351
Visuospatial short-term memory	WAIS IV - Spans	0.00	0.00	0.00	.424
Executive functions					
Inhibition	Stroop (GREFEX) - Interference - Time	26.67	0.00	13.33	.112

Voruz et al. - Long COVID-19 and cognition

	Stroop (GREFEX)- Interference - Errors	6.67	28.57	13.33	.312
	Stroop (GREFEX)- Interference/Naming - Score	13.33	7.14	13.33	.170
Working memory	MEM III – Verbal working memory	6.67	0.00	0.00	.273
	WAIS IV - Visuospatial working memory	6.67	6.67	0.00	.736
	TAP - Working memory item omissions	0.00	0.00	7.14	.664
	TAP - Working memory false alarms	0.00	6.67	14.29	.886
Mental flexibility	TMT A (GREFEX) - Time	0.00	0.00	0.00	.396
	TMT A (GREFEX) - Error	0.00	6.67	13.33	.343
	TMT B (GREFEX) - Time	0.00	13.33	6.67	.093
	TMT B (GREFEX) - Error	6.67	13.33	20.00	.543
	TMT B (GREFEX) - Perseverations	13.33	33.33	20.00	.140
	TMT B-A (GREFEX) - Score	0.00	20.00	6.67	.084
	Verbal fluency (GREFEX) - Literal (2')	6.67	13.33	6.67	.201
	Verbal fluency (GREFEX) - Categorical (2')	13.33	20.00	26.67	.246
ncompatibility	TAP - Compatibility – Reaction time	0.00	0.00	0.00	.834
	TAP - Compatibility - False alarms	0.00	20.00	13.33	.475
	TAP - Incompatibility - Reaction time	0.00	0.00	0.00	.548
	TAP - Incompatibility - False alarms	0.00	20.00	13.33	.528

Voruz et al. - Long COVID-19 and cognition

Interhemispheric transfer	TAP - Incompatibility - Visual field score	13.33	6.67	13.33	.402
	TAP - Incompatibility task - Hands score	6.67	6.67	0.00	.631
Attentional functions					
Phasic alertness	TAP - Without warning sound - Reaction time	13.33	0.00	6.67	.869
	TAP - Without warning sound - SD of reaction time	13.33	0.00	0.00	.597
	TAP - With warning sound - Reaction time	13.33	0.00	0.00	.604
	TAP - With warning sound - SD of reaction time	6.67	0.00	0.00	.256
	TAP - Alertness index	6.67	6.67	0.00	.426
Sustained attention	TAP - Item omissions	13.33	30.77	7.69	.657
	TAP - False alarm	6.67	23.08	7.69	.101
Divided attention	TAP - Audio condition - Reaction time	20.00	13.33	13.33	.242
	TAP - Visual condition - Reaction time	6.67	0.00	0.00	.999
	TAP - Total omissions	6.67	13.33	0.00	.748
	TAP - Total false alarms	0.00	0.00	20.00	.101
Instrumental functions					
Language	BECLA - Semantic image matching	6.67	6.67	13.33	.409
	BECLA - Semantic word matching	6.67	13.33	6.67	.937
	BECLA - Object and action image naming	6.67	6.67	6.67	.879

Voruz et al. - Long COVID-19 and cognition

	BECLA - Word repetition	0.00	0.00	0.00	.369
	BECLA - Nonword repetition	0.00	0.00	6.67	.191
Ideomotor praxis	Evaluation of ideomotor praxis - Symbolic gestures	0.00	0.00	0.00	.057
	Evaluation of ideomotor praxis - Action pantomimes	0.00	0.00	0.00	.222
	Evaluation of ideomotor praxis - Meaningless gestures	13.33	0.00	6.67	.902
Object perception	VOSP - Fragmented letters	0.00	6.67	0.00	.690
	VOSP - Object decision	20.00	33.33	0.00	.229
Spatial perception	VOSP - Number localization	0.00	20.00	6.67	.932
	VOSP - Cubic counting	0.00	6.67	0.00	.772
Logical reasoning	WAIS IV - Puzzle	6.67	6.67	0.00	.299
	WAIS IV - Matrix	0.00	13.33	0.00	.223
Anosognosia	Memory functions	0.00	40.00	40.00	.020
	Executive functions - Inhibition	20.00	26.67	53.33	.508
	Executive functions - Flexibility	20.00	33.33	33.33	.503
	Executive functions - Working memory	6.67	6.67	0.00	.390
Cognitive complaints	QPC	6.67	13.33	0	.041
	Executive complaints (BRIEF-5) (mean $\pm SD$ )	112.47 (± 13.25)	113.20 (± 20.96)	99.60 (± 20.06)	.153
Emotion recognition	GERT – Emotion recognition task (mean $\pm SD$ )	26.53 (± 5.14)	20.33 (± 6.17)	21.6 (± 7.23)	.023

- Note. Prevalence was calculated according to normative scores, ranging from much lower than the norm (below 2<sup>nd</sup> percentile) to substandard (between 2<sup>nd</sup> and 5<sup>th</sup> percentiles). Scores that were borderline or below the normal limit (between 6<sup>th</sup> and 15<sup>th</sup> percentiles) were not
- 3 included.
- 4 **Abbreviations:** BECLA: Batterie d'évaluation cognitive du langage (Macoir et al., 2016); GERT: Geneva Emotion Recognition Test
- 5 (Schlegel et al., 2014); GREFEX: Groupe de Réflexion sur l'Evalutation des Fonctions Exécutives (Roussel & Godefroy, 2008); MEM III:
- 6 Wechsler Memory Scale Third Edition (Drozdick et al., 2018); QPC: Cognitive Complaint Questionnaire (Thomas-Antérion et al., 2004); Rey
- 7 figure: Rey-Osterrieth Complex Figure test (Meyers & Meyers, 1995); RL/RI-16: free/cued recall 16 items (Grober & Buschke, 1987); SD:
- 8 standard deviation; TAP: Test for Attentional Performance (TAP), Version 2.1 (Zimmermann & Fimm, 2007); TMT: Trail Making Test; VOSP:
- 9 Visual Object and Space Perception battery (Warrington & James, 1991); WAIS IV: Wechsler Adult Intelligence Scale–Fourth Edition
- 10 (Wechsler, 2008).

11

12

## Table 3: Psychiatric symptoms and olfaction in patients with mild, moderate or severe COVID-19 6-9 months post-infection

Psychiatric symptoms	Mild (n = 15)	Moderate $(n = 15)$	Severe $(n = 15)$	<b>p</b> value
Depression (BDI-II)	Minor = 46.67%	Minor = 66.67%	Minor = 80%	.009
(prevalence)	Mild = 20%	Mild = 20%	Mild = 20%	
	Moderate = 33.33%	Moderate = 13.33%	Moderate = 0%	
	Severe = 0%	Severe = 0%	Severe = 0%	
State anxiety (STAI-state)	Very low = 26.67%	Very low = 60%	Very low = 86.67%	.002
(prevalence)	Low = 33.33%	Low = 6.67%	Low = 6.67%	
	Moderate = 13.33%	Moderate = 20%	Moderate = 6.67%	
	High = 26.67%	High = 13.33%	High = 0%	
	Very high = 0%	Very high = 0%	Very high = 0%	
Trait anxiety (STAI-trait)	Very low = 46.67%	Very low = 73.33%	Very low = 60%	.100
(prevalence)	Low = 26.67%	Low = 0%	Low = 33.33%	
	Moderate = 13.33%	Moderate = 20%	Moderate = 6.67%	
	High = 13.33%	High = 6.67%	High = 0%	
	Very high = 0%	Very high = 0%	Very high = 0%	

Voruz et al. - Long COVID-19 and cognition

Mania (Goldberg Inventory)	Probably absent = 26.67%	Probably absent = 13.33%	Probably absent = 20%	.909
(prevalence)	Hypomania = 26.67%	Hypomania = 26.67%	Hypomania = 46.67%	
	Close to mania = 20%	Close to mania = 20%	Close to mania = 6.67%	
	Moderate = 26.67%	Moderate = 40%	Moderate = 26.67%	
	Ordinary to severe = 0%	Ordinary to severe = 0%	Ordinary to severe = 0%	
	Severe = 0	Severe = 0	Severe = 0	
Apathy (AMI-total)	Absent = 86.67%	Absent = 93.33%	Absent = 73.33%	.602
(prevalence)	Moderate = 13.33%	Moderate = 6.67%	Moderate = 26.67%	
	High = 0%	High = 0%	High = 0%	
Behavioral apathy (AMI-behavioral)	Absent = 100%	Absent = 100%	Absent = 93.33%	.211
(prevalence)	Moderate = 0%	Moderate = 0%	Moderate = 6.67%	
	High = 0%	High = 0%	High = 0%	
Social apathy (AMI-social)	Absent = 93.33%	Absent = 86.67%	Absent = 73.33%	.940
(prevalence)	Moderate = 6.67%	Moderate = 6.67%	Moderate = 26.67%	
	High = 0%	High = 6.67%	High = 0%	
Emotional apathy (AMI-emotional)	Absent = 73.33%	Absent = 60%	Absent = 40%	.029
(prevalence)	Moderate = 26.67%	Moderate = 40%	Moderate = 33.33%	
	High = 0%	High = 0%	High = 26.67%	

Voruz et al. - Long COVID-19 and cognition

Absent = 86.67%	Absent = 86.67%	Absent = 93.33%	.054
Present = 13.33%	Present = 13.33%	Present = 6.67%	
26.13 (± 9.53)	19.6 (± 7.47)	14.93 (± 9.42)	.023
7.68 (± 11.89)	10.45 (± 9.23)	3.98 (± 3.03)	.140
41.40 (± 7.20)	44.6 (± 4.22)	36.13 (± 8.38)	.002
41.6 (± 7.39)	44.2 (± 8.33)	39.80 (± 11.77)	.416
Pathological = 40.00%	Pathological = 53.33%	Pathological = 26.67%	.036
Absent = 20%	Absent = 46.67%	Absent = 60%	.040
Mild = 40%	Mild = 40%	Mild = 26.67%	
Moderate = 40%	Moderate = 13.33%	Moderate = 13.33%	
Severe = 0%	Severe = 0%	Severe = 0%	
	$26.13 (\pm 9.53)$ $7.68 (\pm 11.89)$ $41.40 (\pm 7.20)$ $41.6 (\pm 7.39)$ Pathological = 40.00%  Mild = 40%  Moderate = 40%	$26.13 (\pm 9.53) \qquad 19.6 (\pm 7.47)$ $7.68 (\pm 11.89) \qquad 10.45 (\pm 9.23)$ $41.40 (\pm 7.20) \qquad 44.6 (\pm 4.22)$ $41.6 (\pm 7.39) \qquad 44.2 (\pm 8.33)$ $Pathological = 40.00\% \qquad Pathological = 53.33\%$ $Absent = 20\% \qquad Absent = 46.67\%$ $Mild = 40\% \qquad Mild = 40\%$ $Moderate = 40\% \qquad Moderate = 13.33\%$	$26.13 (\pm 9.53) \qquad 19.6 (\pm 7.47) \qquad 14.93 (\pm 9.42)$ $7.68 (\pm 11.89) \qquad 10.45 (\pm 9.23) \qquad 3.98 (\pm 3.03)$ $41.40 (\pm 7.20) \qquad 44.6 (\pm 4.22) \qquad 36.13 (\pm 8.38)$ $41.6 (\pm 7.39) \qquad 44.2 (\pm 8.33) \qquad 39.80 (\pm 11.77)$ $Pathological = 40.00\% \qquad Pathological = 53.33\% \qquad Pathological = 26.67\%$ $Absent = 20\% \qquad Absent = 46.67\% \qquad Absent = 60\%$ $Mild = 40\% \qquad Mild = 40\% \qquad Mild = 26.67\%$ $Moderate = 40\% \qquad Moderate = 13.33\% \qquad Moderate = 13.33\%$

Voruz et al. - Long COVID-19 and cognition

Fatigue (EMIF-SEP)	Present = 13.33%	Present = 20%	Present = 6.67%	.088
(prevalence)				
Sniff test (anosmia)	13.07 (± 1.44)	11.53 (± 2.13)	11.47 (± 2.90)	.067
Mean (± SD)				

Abbreviations: AMI-behavioral: Apathy Motivation Index – behavioral score (Ang et al., 2017); AMI-emotional: Apathy Motivation Index – emotional score (Ang et al., 2017); AMI-social: Apathy Motivation Index – social score (Ang et al., 2017); AMI-total: Apathy Motivation Index – total score (Ang et al., 2017); BDI-II: Beck Depression Inventory-Second edition (Beck et al., 1996); DES: Dissociative Experience Scale (Carlson & Putnam, 1986); ECS: Emotion Contagion Scale (Doherty, 1997); EMIF-SEP: Fatigue Impact Scale, French adaptation (Debouverie et al., 2007); ERQ: Emotion Regulation Questionnaire (Gross & John, 2003); Epworth: Epworth Sleepiness Scale (Johns, 1991); Goldberg Inventory: Goldberg Mania Inventory (Goldberg, 1993); ISI: Insomnia Severity Index (Morin, 1993); PCL-5: Posttraumatic Stress Disorder Checklist for DSM-5 (Ashbaugh et al., 2016); PSS-14: Perceived Stress Scale – 14 items (Lesage et al., 2012); STAI-trait: State-Trait Anxiety Inventory (Spielberger et al., 1993); STAI-state: State-Trait Anxiety Inventory (Spielberger et al., 1993).

### Neuropsychological and psychiatric symptoms as a function of disease

severity 22

21

28

- 23 The second aim was to determine whether cognitive deficits and psychiatric symptoms are a
- 24 function of the severity of the respiratory symptoms in the acute phase. To this end, we
- 25 compared the three groups on neuropsychological, psychiatric and other clinical data
- (Kruskal-Wallis statistics and p values reported in Tables 2, 3 and 4; Bonferroni-corrected 26
- 27 Mann-Whitney statistics and p values reported below).
- 29 i)*Neuropsychological data (Fig. 2)*
- 30 The three groups differed significantly on i) long-term episodic memory in both the
- 31 verbal (Grober and Buschke (RL/RI 16) delayed free recall, H = 10.75, p = .005) and visual
- 32 (Rey Figure delayed free recall, H = 6.15, p = .046) modalities, ii) multimodal emotion
- 33 recognition (GERT; H = 7.55, p = .023), iii) cognitive complaints (QPC; H = 6.38, p = .041)
- 34 and anosognosia for memory dysfunction (SAD; H = 7.84, p = .020). The other effects were
- 35 not significant (p > .05 for all comparisons).
- 36 Episodic memory. For Grober and Buschke delayed free recall, the mild patients
- 37 scored significantly higher than the severe patients (z=3.04, p=.002), but the other two
- 38 pairwise comparisons were not significant after Bonferroni correction (moderate vs. severe: z
- 39 = -1.47, p = .141; mild vs. moderate: z = 2.00, p = .046). Pairwise comparisons were not
- 40 significant for visual episodic memory (mild vs. moderate: z = 2.26, p = .023; mild vs. severe:
- z = 0.48, p = .61; moderate vs. severe: z = 1.89, p = .059). 41
- *Emotion recognition.* Mild patients scored significantly higher than moderate patients 42
- 43 (z = 2.61, p = 0.009), but neither the difference between mild and severe patients (z = 1.97, p = 0.009)
- 44 = 0.048), nor the difference between moderate and severe patients (z = .49, p = .620) reached
- 45 significance after Bonferroni correction.

46

47

48

49

50

51

52

53

54

55

Cognitive complaints and anosognosia. Mild patients had more cognitive complaints than severe patients (z = -2.55, p = .010), but there were no differences between either the mild and moderate patients (z = -1.31, p = .191), or the moderate and severe patients (z = -1.31, z = -1.31), or the moderate and severe patients (z = -1.31). 0.93, p = .351). By contrast, severe patients exhibited more anosognosia for memory dysfunction than mild patients did (z = 2.97, p = .003), while there were no differences between either the mild and moderate patients (z = 1.41, p = .158) or the moderate and severe patients (z = -0.76, p = .443).




Figure 2. Mean ratings (and standard deviations) for all three groups (severe in black, moderate in gray, and mild in orange) on tasks evaluating verbal episodic memory

perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

Long COVID-19 and cognition

76

77

(A1), anosognosia for memory dysfunction (B1), and multimodal emotion recognition 56 57 (C1), as well as their respective predictors (A2, B2 and C2) **Note.** A2: The greater the emotional apathy, the poorer the performance on verbal 58 59 memory (except for the mild group); B2: The lower the depression, the greater the anosognosia for memory dysfunction; C2: The poorer the olfactory recognition, the poorer the 60 61 emotion recognition. 62 ii) Psychiatric data 63 64 The three groups differed significantly on depression (H = 9.40, p = .009), state anxiety (H = 12.93, p = .002), emotional apathy (H = 7.10, p = .029), stress (H = 7.55, p = .002) 65 .023), and emotional contagion (H = 9.73, p = .002). The other effects were not significant (p66 67 > .05 for all comparisons). Pairwise comparisons for each of these group differences are 68 described below. 69 Depression, stress, and state anxiety. The mild patients were more depressed, stressed and anxious than the severe patients (BDI-II: z = -2.99, p = .003; PSS: z = -2.55, p = .010; 70 71 STAI-S: z = -3.57, p < .001), while there were no differences between either the severe and 72 moderate patients (BDI-II: z = -1.38, p = .165; PSS: z = -1.08, p = .281; STAI-S: z = -1.76, p = .281; STAI-S: z = -1.76, p = .281; STAI-S: z = -1.76, z = -1.7673 = .078) or the mild and moderate patients (BDI II: z = -1.66, p = .097; PSS: z = -1.08, p =74 .281; STAI-S: z = -1.72, p = .085). 75 *Apathy*. For the AMI emotional subscore, pairwise comparisons failed to reach

significance after Bonferroni correction (severe vs. mild: z = 2.32, p = .020; severe vs.

moderate: z = 2.20, p = .028, mild vs. moderate: z = 0.08, p = .933).

78	Emotional contagion. Pairwise comparisons failed to reach significance after
79	Bonferroni correction (severe vs. moderate: $z = -3.03$ , $p = .017$ ; severe vs. mild: $z = -1.89$ , $p =$
80	.059; moderate vs. mild: $z = 1.18$ , $p = .237$ ).
81	
82	iii) Fatigue and quality of life
83	Finally, the three groups differed on insomnia ( $H = 6.66$ , $p = .036$ ), fatigue ( $H = 6.45$ ,
84	p = .040), vitality ( $H = 6.50$ , $p = .039$ ), and emotional wellbeing ( $H = 9.18$ , $p = .010$ ). The
85	other effects were not significant ( $p > .05$ for all comparisons).
86	The mild patients reported more fatigue than the severe patients ( $z = -2.57$ , $p = .010$ ),
87	while there were no differences between either the mild and moderate patients ( $z = -0.71$ , $p =$
88	.481) or both moderate and severe patients ( $z = -1.52$ , $p = .130$ ). Pairwise comparisons did not
89	reach significance after Bonferroni correction (mild vs. moderate: $z = -1.99$ , $p = .046$ ; mild vs.
90	severe: $z = -2.28$ , $p = .023$ ; moderate vs. severe: $z = -0.71$ , $p = .481$ ).
91	Conversely, severe patients reported more vitality, emotional wellbeing and social
92	function than mild patients (vitality: $z = 2.65$ , $p = .008$ ; wellbeing: $z = 2.97$ , $p = .003$ ; social
93	function: $z = 2.99$ , $p = .002$ ). Pairwise comparisons between severe and moderate patients did
94	not reach significance after Bonferroni correction (wellbeing: $z = 2.01$ , $p = .044$ ; vitality: $z =$
95	1.06, $p = .290$ ; social function: $z = 1.66$ , $p = .097$ ), nor did those between mild and moderate
96	patients (wellbeing: $z = 0.68$ , $p = .494$ ; vitality: $z = 1.12$ , $p = .263$ ; social function: $z = 1.06$ , $p$
97	= .290) (see Table 4).
98	

### Table 4: Quality of life of patients with mild, moderate or severe COVID-19 6-9

### months post-infection

99

100

101

102

103

104

Quality of life domains (SF-36) <sup>+</sup>	Mild (n = 15)	Moderate $(n = 15)$	Severe $(n = 15)$	<b>p</b> value
	Mean $(\pm SD)$	Mean $(\pm SD)$	Mean $(\pm SD)$	
Overall health	62.67 (± 16.89)	59.33 (± 27.31)	66.00 (± 24.14)	.808
Physical function	80.00 (± 17.22)	82.33 (± 19.44)	77.33 (± 24.41)	.806
Physical role	58.33 (± 30.86)	53.33 (± 43.16)	71.67 (± 36.43)	.353
Emotional role	64.45 (± 36.67)	73.34 (± 36.08)	80.00 (± 37.38)	.314
Social function	57.50 (± 23.05)	66.67 (± 31.93)	85.00 (± 18.42)	.011
Physical pain	57.83 (± 20.81)	72.00 (± 29.40)	71.83 (± 25.61)	.153
Emotional wellbeing	58.13 (± 17.75)	61.33 (± 24.96)	79.2 (± 17.90)	.010
Vitality score	38.66 (± 16.20)	49.00 (± 27.14)	56.00 (± 14.17)	.039
Health modification	30.00 (± 16.90)	35.00 (± 24.64)	43.33 (± 17.59)	.143

<sup>&</sup>lt;sup>+</sup> The higher the score, the better the quality of life.

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

# Relationships between neuropsychological deficits, psychiatric symptoms,

### and other secondary variables

The third aim was to examine whether the presence of long-term neuropsychological deficits was correlated with psychiatric symptoms and/or other clinically relevant variables.

The results of the multiple regression performed on each cognitive variable are set out in Table 5. Interestingly, apathy, depression, anxiety, emotion regulation, emotion contagion, stress, PTSD, dissociative disorders, anosmia and diabetes all proved to be variables of interest when it came to explaining the neuropsychological sequelae. Therefore, both psychiatric and nonpsychiatric data correlated with neuropsychological deficits across the three groups. There were at least three patterns of results, depending on the neuropsychological domain: i) patterns in which neuropsychological sequelae did not correlate with any psychiatric variables, but did with other clinical variables, such as visuospatial long-term episodic memory (delayed recall of Rey-Osterrieth complex figure); ii) patterns in which neuropsychological sequelae correlated with both psychiatric and clinical variables, such as the object and action naming task scores (language); and iii) patterns in which neuropsychological sequelae only correlated with psychiatric variables, such as categorical verbal fluency. There was also a fourth possible pattern where the neuropsychological sequelae correlated neither with psychiatric variables nor with clinical ones, such as the score on the object decision task (object perception).

To reduce the dimensionality of the dataset, we computed a PCA. We selected the first three orthogonal components accounting for 43.67% of the total variance. The first component, accounting for 26.75% of the total variance, was difficult to interpret in terms of underlying cognitive processes, as it included language (semantic word and image matching), executive functions (mental flexibility), verbal episodic memory, and emotion recognition.

129

130

131

132

133

134

135

136

137

138

139

140

141

Interestingly, these happened to be precisely the variables on which the three groups differed significantly (see Section "Neuropsychological and psychiatric symptoms as a function of disease severity"). We therefore labeled this component respiratory disease severity. The second component (9.79% of total variance) was labeled attention and anosognosia, as it included alertness, divided attention, and anosognosia for executive dysfunction. The third component (7.15% of total variance) was labeled instrumental functions, as it included language, visual perception, and ideomotor praxis. For the respiratory disease severity component, the best fit was achieved with emotional apathy ( $R^2 = .28$ , p = .007), stress ( $R^2 = .19$ , p = .013), and anosmia ( $R^2 = .11$ , p = .013) .03). For the attention and anosognosia component, the multiple regression was not significant (p > .1). For the instrumental functions component, the best fit was achieved with anosmia  $(R^2)$ = .23, p = .04), mania ( $R^2 = .23$ , p = .006), and social apathy ( $R^2 = .17$ , p = .004).

### 142 Table 5. Multiple regression results for each of the neuropsychological variables

Memory functions         Verbal episodic memory         Grober & Buschke (RL/RI 16) - ns         ns         ns         ns           Immediate recall           Epworth - Sleepiness         .20         .022           ERQ - Emotion regulation         .13         .034           ECS - Emotion contagion         .08         .034           Grober & Buschke (RL/RI 16) - AMI - Emotional apathy         .34         .022           Delayed total recall           Epworth - Sleepiness         .22         .031           AMI - Social apathy         .15         .034           Visuospatial episodic         Rey Figure - Copy time         ISI - Insomnia         .46         .005           memory           ERQ - Emotional         .18         .035           regulation           Rey Figure - Score         ns         ns         ns           Rey Figure - Immediate recall (3')         ns         ns         ns           Days of hospitalization         .22         .039		Regressor		$R^2$ p value	
Verbal episodic memory       Grober & Buschke (RL/RI 16) - Immediate recall       ns       ns	Memory functions				
Immediate recall  Grober & Buschke (RL/RI 16) - AMI - Emotional apathy .45 .006  Delayed free recall  Epworth - Sleepiness .20 .022  ERQ - Emotion regulation .13 .034  ECS - Emotion contagion .08 .034  Grober & Buschke (RL/RI 16) - AMI - Emotional apathy .34 .022  Delayed total recall  Epworth - Sleepiness .22 .031  AMI - Social apathy .15 .034  Visuospatial episodic Rey Figure - Copy time ISI - Insomnia .46 .005  memory  ERQ - Emotional .18 .035  regulation  Rey Figure - Score		Grober & Buschke (RL/RL16) -	ns	ns	ns
Grober & Buschke (RL/RI 16) - AMI – Emotional apathy .45 .006  Delayed free recall  Epworth - Sleepiness .20 .022  ERQ – Emotion regulation .13 .034  ECS – Emotion contagion .08 .034  Grober & Buschke (RL/RI 16) - AMI – Emotional apathy .34 .022  Delayed total recall  Epworth - Sleepiness .22 .031  AMI – Social apathy .15 .034  Visuospatial episodic Rey Figure - Copy time ISI - Insomnia .46 .005  memory  ERQ – Emotional .18 .035  regulation  Rey Figure - Score ns ns ns ns  Rey Figure - Immediate recall (3') ns ns ns ns  Rey Figure - Delayed recall (20') ISI – Insomnia .30 .034	versus episodic memory		11.5	713	713
Epworth - Sleepiness   .20   .022					
Epworth - Sleepiness .20 .022  ERQ - Emotion regulation .13 .034  ECS - Emotion contagion .08 .034  Grober & Buschke (RL/RI 16) - AMI - Emotional apathy .34 .022  Delayed total recall  Epworth - Sleepiness .22 .031  AMI - Social apathy .15 .034  Visuospatial episodic Rey Figure - Copy time ISI - Insomnia .46 .005  memory  ERQ - Emotional .18 .035  regulation  Rey Figure - Score ns ns ns ns  Rey Figure - Immediate recall (3') ns ns ns  Rey Figure - Delayed recall (20') ISI - Insomnia .30 .034		Grober & Buschke (RL/RI 16) -	AMI – Emotional apathy	.45	.006
ERQ – Emotion regulation .13 .034  ECS – Emotion contagion .08 .034  Grober & Buschke (RL/RI 16) - AMI – Emotional apathy .34 .022  Delayed total recall  Epworth - Sleepiness .22 .031  AMI – Social apathy .15 .034  Visuospatial episodic Rey Figure - Copy time ISI - Insomnia .46 .005  memory  ERQ – Emotional .18 .035  regulation  Rey Figure - Score ns ns ns ns  Rey Figure - Immediate recall (3') ns ns ns  Rey Figure - Delayed recall (20') ISI – Insomnia .30 .034		Delayed free recall			
ECS – Emotion contagion .08 .034  Grober & Buschke (RL/RI 16) - AMI – Emotional apathy .34 .022  Delayed total recall  Epworth - Sleepiness .22 .031  AMI – Social apathy .15 .034  Visuospatial episodic Rey Figure - Copy time ISI - Insomnia .46 .005  memory  ERQ – Emotional .18 .035  regulation  Rey Figure - Score ns ns ns ns  Rey Figure - Immediate recall (3') ns ns ns  Rey Figure - Delayed recall (20') ISI – Insomnia .30 .034			Epworth - Sleepiness	.20	.022
Grober & Buschke (RL/RI 16) - AMI – Emotional apathy .34 .022  Delayed total recall  Epworth - Sleepiness .22 .031  AMI – Social apathy .15 .034  Visuospatial episodic Rey Figure - Copy time ISI - Insomnia .46 .005  memory  ERQ – Emotional .18 .035  regulation  Rey Figure - Score ns ns ns ns  Rey Figure - Immediate recall (3') ns ns ns  Rey Figure - Delayed recall (20') ISI – Insomnia .30 .034			ERQ – Emotion regulation	.13	.034
Delayed total recall  Epworth - Sleepiness .22 .031  AMI - Social apathy .15 .034  Visuospatial episodic Rey Figure - Copy time ISI - Insomnia .46 .005  memory  ERQ - Emotional .18 .035  regulation  Rey Figure - Score ns ns ns ns  Rey Figure - Immediate recall (3') ns ns ns ns  Rey Figure - Delayed recall (20') ISI - Insomnia .30 .034			ECS – Emotion contagion	.08	.034
Epworth - Sleepiness .22 .031  AMI – Social apathy .15 .034  Visuospatial episodic Rey Figure - Copy time ISI - Insomnia .46 .005  memory  ERQ – Emotional .18 .035  regulation  Rey Figure - Score ns ns ns ns  Rey Figure - Immediate recall (3') ns ns ns  Rey Figure - Delayed recall (20') ISI – Insomnia .30 .034		Grober & Buschke (RL/RI 16) -	AMI – Emotional apathy	.34	.022
AMI – Social apathy .15 .034  Visuospatial episodic Rey Figure - Copy time ISI - Insomnia .46 .005  memory  ERQ – Emotional .18 .035  regulation  Rey Figure - Score ns ns ns ns  Rey Figure - Immediate recall (3') ns ns ns  Rey Figure - Delayed recall (20') ISI – Insomnia .30 .034		Delayed total recall			
Visuospatial episodic Rey Figure - Copy time ISI - Insomnia .46 .005  memory  ERQ - Emotional .18 .035  regulation  Rey Figure - Score ns ns ns ns  Rey Figure - Immediate recall (3') ns ns ns  Rey Figure - Delayed recall (20') ISI - Insomnia .30 .034			Epworth - Sleepiness	.22	.031
memory  ERQ – Emotional .18 .035 regulation  Rey Figure - Score ns ns ns ns  Rey Figure - Immediate recall (3') ns ns ns  Rey Figure - Delayed recall (20') ISI – Insomnia .30 .034			AMI – Social apathy	.15	.034
ERQ – Emotional .18 .035  regulation  Rey Figure - Score ns ns ns  Rey Figure - Immediate recall (3') ns ns ns  Rey Figure - Delayed recall (20') ISI – Insomnia .30 .034	Visuospatial episodic	Rey Figure - Copy time	ISI - Insomnia	.46	.005
regulation  Rey Figure - Score ns ns ns ns  Rey Figure - Immediate recall (3') ns ns ns  Rey Figure - Delayed recall (20') ISI – Insomnia .30 .034	memory				
Rey Figure - Score ns ns ns ns  Rey Figure - Immediate recall (3') ns ns ns  Rey Figure - Delayed recall (20') ISI – Insomnia .30 .034			ERQ – Emotional	.18	.035
Rey Figure - Immediate recall (3') ns ns ns ns  Rey Figure - Delayed recall (20') ISI – Insomnia .30 .034			regulation		
Rey Figure - Delayed recall (20') ISI – Insomnia .30 .034		Rey Figure - Score	ns	ns	ns
		Rey Figure - Immediate recall (3')	ns	ns	ns
Days of hospitalization 22 030		Rey Figure - Delayed recall (20')	ISI – Insomnia	.30	.034
Days of nospitalization .22 .039			Days of hospitalization	.22	.039
Sniff test (anosmia) .21 .013			Sniff test (anosmia)	.21	.013
Verbal short-term memory MEM III - Spans ns ns ns	Verbal short-term memory	MEM III - Spans	ns	ns	ns
Visuospatial short-term WAIS IV - Spans DES – Dissociation .30 .035	Visuospatial short-term	WAIS IV - Spans	DES – Dissociation	.30	.035
memory	memory				

<b>Executive functions</b>				
Inhibition	Stroop (GREFEX) - Interference	ns	ns	ns
	- Time			
	Stroop (GREFEX)- Interference -	AMI – Total apathy	.37	.015
	Errors			
		ERQ – Emotion regulation	.21	.030
	Stroop (GREFEX) -	ns	ns	ns
	Interference/Naming - Score			
Working memory	MEM III – Verbal working	AMI – Behavioral apathy	.33	.026
	memory			
	WAIS IV - Visuospatial working	STAI-T Anxiety	.39	.013
	memory			
		Diabetes	.25	.014
		STAI-S Anxiety	.13	.03
	TAP - Working memory item	AMI – Emotional apathy	.30	.035
	omissions			
	TAP - Working memory false	Diabetes	.47	.005
	alarms			
		Mania – Goldberg	.16	.044
		Inventory		
Mental flexibility	TMT A (GREFEX) - Time	ns	ns	ns
	TMT A (GREFEX) - Errors	ns	ns	ns
	TMT B (GREFEX) - Time	ns	ns	ns
	TMT B (GREFEX) - Errors	AMI – Total apathy	.41	.010
		ERQ – Emotion regulation	.14	.024
		Gender	.13	.025

	TMT B (GREFEX) -	STAI-T Anxiety	.55	.002
	Perseverations			
		BDI-II - Depression	.16	.026
		ISI – Insomnia	.20	<.001
	TMT B-A (GREFEX) - Score	ns	ns	ns
	Verbal fluency (GREFEX) -	ns	ns	ns
	Literal (2')			
	Verbal fluency (GREFEX) -	DES - Dissociation	.28	.047
	Categorical fluency (2')			
Incompatibility	TAP - Compatibility – Reaction	AMI – Social apathy	.50	.003
	time			
	TAP - Compatibility - False	ns	ns	ns
	alarms			
	TAP - Incompatibility - Reaction	Sniff test (anosmia)	.28	.043
	Time			
		DES - Dissociation	.25	.026
		ERQ – Emotion regulation	.13	.028
		Epworth - Sleepiness	.10	.017
	TAP - Incompatibility - False	Sniff test (anosmia)	.27	.045
	alarms			
	TAP - Incompatibility - Visual	Days of hospitalization	.39	.013
	field score			
		Diabetes	.23	.007
		STAI-T Anxiety	.08	.041
		PCL-5 Posttraumatic stress	.06	.041
		disorder		
	TAP - Incompatibility task -	AMI – Social apathy	.44	.008
	Hands score			

	TAP - Incompatibility task -	ISI – Insomnia	.33	.025
	Visual fields * Hands score			
		STAI-T Anxiety	.24	.025
		BDI-II - Depression	.18	.019
<b>Attentional functions</b>				
Phasic alertness	TAP - Without warning sound -	Gender	.35	.019
	Reaction time			
	TAP - Without warning sound -	AMI – Social apathy	.64	<.001
	SD of reaction time			
		Diabetes	.11	.041
		Sniff test (anosmia)	.10	.023
	TAP - With warning sound -	DES - Dissociation	.30	.033
	Reaction time			
	TAP - With warning sound - SD	ns	ns	ns
	of reaction time			
	TAP - Alertness index	Gender	.28	.041
Sustained attention	TAP - Items Omissions	STAI-Trait Anxiety	.46	.005
	TAP - False alarm	ns	ns	ns
Divided attention	TAP - Audio condition - Reaction	DES - Dissociation	.41	.010
	time			
		AMI – Behavioral apathy	.27	.008
	TAP - Visual condition -	Days of hospitalization	.38	.014
	Reaction time			
		Sniff test (anosmia)	.27	.009
		ISI - Insomnia	.23	<.001
		AMI – Emotional apathy	.05	.016
	TAP - Total omissions	ns	ns	ns
	TAP - Total false alarms	AMI – Emotional apathy	.32	.029

		Epworth - Sleepiness	.28	.015
		AMI – Social apathy	.16	.023
Instrumental functions				
Language	BECLA - Semantic image	ns	ns	ns
	matching			
	BECLA - Semantic word	ns	ns	ns
	matching			
	BECLA - Object and action	ECS – Emotional contagion	.38	.014
	image naming			
		STAI-State Anxiety	.29	.007
		AMI – Emotional apathy	.10	.014
		ISI - Insomnia	.08	.012
	BECLA - Word repetition	NV	NV	NV
	BECLA - Nonword repetition	ns	ns	ns
Ideomotor praxis	Symbolic gestures	ERQ – Emotion regulation	.35	.019
		AMI – Behavioral apathy	.33	.004
	Action pantomimes	BDI-II - Depression	.51	.003
	Meaningless gestures	AMI – Total apathy	.30	.033
		AMI – Social apathy	.18	.035
Object perception	VOSP - Fragmented letters	AMI – Total apathy	.26	.029
	VOSP - Object decision	ns	ns	ns
Spatial perception	VOSP - Number localization	ns	ns	ns
	VOSP - Cubic counting	Mania – Goldberg	.27	.047
		Inventory		
		PSS - Stress	.24	.034
Logical reasoning	WAIS IV - Puzzle	Diabetes	.34	.021
	WAIS IV - Matrix	DES - Dissociation	.28	.041
		Gender	.40	.002

143

144

145

146

147

148

149

150

151

152

153

154

Emotion recognition	GERT	ERQ – Emotion regulation	.33	.023
		AMI – Emotional apathy	.28	.011
		AMI – Behavioral apathy	.16	.004
		Sniff test (anosmia)	.06	.008
		AMI – Social apathy	.02	.027
Anosognosia	Memory dysfunctions	BDI-II - Depression	.62	<.001
		ISI - Insomnia	.12	.038
		AMI – Behavioral apathy	.09	.040
		Epworth - Sleepiness	.05	.033
	Executive functions - Inhibition	AMI – Total apathy	.40	.011
	Executive functions - Flexibility	AMI – Behavioral score	.28	.043
	Executive functions – Working memory	Epworth - Sleepiness	.38	.015
		Sniff test (anosmia)	.25	.015

**Abbreviations:** AMI-behavioral: Apathy Motivation Index – behavioral score (Ang et al., 2017); AMI-emotional: Apathy Motivation Index – emotional score (Ang et al., 2017); AMI-social: Apathy Motivation Index – social score (Ang et al., 2017); AMI-total: Apathy Motivation Index – total score (Ang et al., 2017); BDI-II: Beck Depression Inventory-Second Edition (Beck et al., 1996); BECLA: Batterie d'Evaluation Cognitive du Langage (Macoir et al., 2016); DES: Dissociative Experience Scale (Carlson & Putnam, 1986); ECS: Emotion Contagion Scale (Doherty, 1997); ERQ: Emotion Regulation Questionnaire (Gross & John, 2003); GERT: Geneva Emotion Recognition Test (Schlegel et al., 2014); Goldberg-Inventory: Goldberg Mania Inventory (Goldberg, 1993); GREFEX: Groupe de Réflexion sur l'Evalutation des Fonctions Exécutives (Roussel & Godefroy, 2008); MEM III: Wechsler Memory Scale – Third Edition (Drozdick et al., 2018); NV: no variance; ns: not significant; PCL-5: Posttraumatic Stress Disorder Checklist for DSM-5 (Ashbaugh et al., 2016); PSS-14:

155	Perceived Stress Scale – 14 items (Lesage et al., 2012); Rey figure: Rey-Osterrieth Complex
156	Figure test (Meyers & Meyers, 1995); RL/RI 16: free/cued recall 16 items (RL/RI-16)
157	(Grober & Buschke, 1987); SD: standard deviation; STAI-S: State-Trait Anxiety Inventory
158	(Spielberger et al., 1993) STAI-T: State-Trait Anxiety Inventory (Spielberger et al., 1993);
159	TAP: Test for Attentional Performance (TAP), Version 2.1 (Zimmermann & Fimm, 2007);
160	TMT: Trail Making Test; VOSP: Visual Object and Space Perception battery (Warrington &
161	James, 1991); WAIS IV: Wechsler Adult Intelligence Scale-Fourth Edition (Wechsler, 2008).

# **DISCUSSION**

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

Even though there is growing evidence that SARS-CoV-2 can cause brain damage in the long term, with an impact on cognition even in its mild and moderate forms, to date, the occurrence and nature of such sequelae, the impact of respiratory disease severity in the acute phase, and the relationship between these impairments and psychiatric disorders triggered or exacerbated by the pandemic have not been studied in detail within a single sample of patients. In addition, areas such as instrumental functions (ideomotor praxis, visual perception, or language), cognitive complaints, anosognosia, and emotion recognition following SARS-CoV-2 have yet to be explored. Finally, the relevant medical events have not been controlled in studies published thus far. The present study used a robust, psychometrically validated methodology and a stringent approach to the normative data of neuropsychological tests (excluding borderline scores from the prevalence calculation). We included patients with no history of cancer or neurological and developmental disorders, and no active psychiatric disorders before SARS-CoV-2 infection, and divided them into mild, moderate and severe groups, according to the respiratory severity of the disease during its acute phase. The present study therefore improves our understanding of what we can call neurological long COVID, highlighting three main patterns of results. First, important prevalence of patients across the three groups performed below the normality threshold in all domains of cognition (except ideomotor praxis) 6-9 months post-infection with SARS-CoV-2. The prevalence of psychiatric symptoms, regardless of disease severity during the acute phase, was also high, and individuals in all three groups exhibited depressive symptoms, anxiety, mania, apathy, stress, PTSD and dissociative disorders, as well as reporting insomnia, fatigue and pathological somnolence. Regarding olfaction, 33.33% of the mild group, 73.33% of the moderate group, and 46.66% of the severe group were still hyposmic 6-9 months

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

following infection, and 13.33% of the severe group were still anosmic. Second, despite the presence of common cognitive deficits across the three groups, some domains of cognition and mood were differentially impacted by the severity of respiratory disease during the acute phase: the severe group performed more poorly than the mild group on long-term episodic memory, and also exhibited more anosognosia for memory dysfunction. The mild group was more depressed, stressed and anxious, and reported more cognitive complaints. Finally, the moderate group recognized multimodal emotions less well than the mild group. All of this had a substantial impact on patients' quality of life. Third, as predicted, neuropsychological deficits correlated with psychiatric disorders such as depressive symptoms, stress and mania, but not all of the variance was explained by psychiatric symptoms or transdiagnostic syndrome (Husain & Roiser, 2018). A large proportion of the variance was explained by other clinical variables. For instance, the long-term episodic memory deficits displayed by the severe group were positively correlated with emotional apathy, their anosognosia for memory dysfunction was correlated with depression, and their diminished emotion recognition, shared by the moderate group, was positively correlated with hyposmia and/or anosmia. The present study had several limitations that need to be acknowledged and addressed before we can draw any inferences from our results. The first drawback was a possible recruitment bias. By enrolling volunteers, we may have selected the most severe cases in the mild group (who were interested in the study because of their cognitive complaints), while we may not have recruited the most cognitively affected in the severe group, because they were too disabled to join the study. Second, we had greater proportions of men and diabetics in the severe group. These factors may have had an influence on the cognitive deficits observed in this group, as diabetes is known to impact cognition (McCrimmon, Ryan, & Frier, 2012), and gender on depression (Spagnolo, Manson, & Joffe, 2020), with a greater prevalence in women perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

## Long COVID-19 and cognition

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

(Mazza et al., 2020). That said, although the proportion of women was higher for both the mild and moderate groups, the mean depression scores by gender in the mild (women:  $13.50 \pm$ 9.10; men:  $12.57 \pm 8.52$ ) and moderate (women:  $6.11 \pm 5.25$ ; men:  $13.33 \pm 11.25$ ) groups did not indicate a greater proportion of women with depressive symptoms. Third, stroke is more prevalent in patients after a severe SARS-CoV-2 infection (Merkler et al., 2020; Nannoni et al., 2020), and may have gone unseen during the acute phase. In our study, no patient had any central neurological deficit excluding major stroke, but minor stroke cannot be ruled out. Two patients in the severe group reported mild signs of peripheral neuropathy, which may have been due to their diabetes and not a direct consequence of the SARS-CoV-2 infection, while one patient in the severe group had an unstable gait. Fourth, the absence of a control group prevented us from observing a possible general effect of the pandemic and the resulting public health measures on mental health. In the present study, the analyses of prevalence were based on standardized normative data, allowing us to run comparisons with the normal population. The tests were chosen carefully for their psychometric validity, with adequate sensitivity and specificity. It is interesting to note that in a recent study, our multimodal emotion recognition task (GERT) was administered to 469 participants during the pandemic (Schlegel, von Gugelberg, Makowski, Gubler, & Troche, 2021) but the authors failed to find a reduction in performances compared with validation studies (Schlegel et al., 2014), reinforcing the hypothesis that our results reflected a specific effect of the infection and not just the public health context. Fifth and last, it is important to note the relatively small number of participants, which prevented us from considering more covariates. Nevertheless, the power analysis, based on a previous study of the neurocognitive effects of SARS-CoV-2, did allow us to estimate the necessary sample size.

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

The present results demonstrate that cognitive deficits can be observed 6-9 months post-SARS-CoV-2 infection, regardless of the severity of the disease in the acute phase. They corroborate previous observations for the executive, attentional and memory domains, and go one step further, with exhaustive neuropsychological and psychiatric assessments demonstrating impairments in other previously unexplored cognitive and psychiatric domains. Impairments were evident not only in the severe patient group, but also in the moderate and mild groups. These deficits had an impact on quality of life, notably in the mild patients, as evidenced by our results. These findings could be of great importance in understanding the long-term damage and consequences of SARS-CoV-2 infection on cognition and mental health. The relatively high prevalence of certain cognitive and psychiatric disorders, regardless of the severity of the disease in the acute phase, suggests that long-term patient management following SARS-CoV-2 infection may need to be adapted. Importantly, the etiology of these disorders needs to be established, in order to provide people experiencing these long-term sequelae with the best possible care. One potential explanation for these effects, based on observational studies of the psychiatric impact of the pandemic in the general population (Bäuerle et al., 2020), is that these cognitive deficits result from a stressful or traumatic context. In this case, specific interventions on certain psychiatric variables could considerably reduce their long-term impact on cognition and improve daily functioning. Nevertheless, the present results do not exclude the hypothesis of direct damage of brain networks by SARS-CoV-2 and its neurotropism, as well as indirect neurobiological effects, which could lead to both to psychiatric and neurological disorders. COVID-19 may induce CNS disturbance, and four main pathogenic mechanisms may act in combination: i) direct viral encephalitis, ii) systemic inflammation, iii) peripheral organ dysfunction (liver, kidney, lung), and iv) cerebrovascular changes (Iadecola, Anrather, & Kamel, 2020). At this stage, it

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

is difficult to determine whether the cognitive deficits can be regarded as a marker of brain damage, and/or should be linked to psychiatric variables that may themselves result directly from infection with SARS-CoV-2 or else be triggered by the stressful nature of the general pandemic and the individual experience of the disease. Second, this study highlighted the presence of differential cognitive and psychiatric profiles at 6-9 months post-infection as a function of the respiratory severity of the SARS-CoV-2 infection in the acute phase. This suggests the existence of different clinical phenotypes. In the identification/discrimination of these phenotypes, different cognitive variables seem to be of interest, starting with cognitive complaints and anosognosia. While the severe patients exhibited anosognosia for their memory dysfunction and greater long-term verbal memory impairment than the mild patients did, the latter had more cognitive complaints. This fits in well with the observations of Almeria et al. (2020), who found that the patients with the most serious cognitive complaints did not have significantly more neuropsychological impairments. In this sense, the tendency of the severe patients to report greater wellbeing in quality-of-life assessments, together with the lack of awareness of their cognitive difficulties, may be a clinical characteristic to bear in mind when interviewing this type of patient. The present results in the domain of emotion recognition and episodic memory are also highly relevant to the current debate on the neurotropism of SARS-CoV-2. One of the main hypotheses regarding the pathways of direct attack of the CNS assumes olfactory transmucosal invasion by the virus (Meinhardt et al., 2021). This hypothesis appears to be supported by our results. It is worth noting that episodic memory and emotion recognition were identified in a PCA as variables that explained most of the variance of our data, and this first component was significantly correlated with hyposmia/anosmia, in addition

to stress and emotional apathy. Interestingly, a recent <sup>18</sup>F-FDG PET study demonstrated

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

hypometabolism at about 8 weeks post-infection in brain regions common to emotion and olfaction in patients with SARS-CoV-2 (Guedj et al., 2020). Moreover, the literature suggests that the viral load was probably greater in our severe group (Fajnzylber et al., 2020; Magleby et al., 2020), which may have contributed to stronger effects on olfaction and emotion recognition. This pathway could also partially explain the psychiatric results via disruption of the limbic network, including subcortical regions (Lane, 2008), by SARS-CoV-2. Our third level of analysis enabled us to go further in characterizing the hypothesized clinical phenotypes. Quantified results pointed to the presence of at least three profiles (patient clusters), corroborating the clinical impressions we had when interviewing and assessing the patients for this study. Patients with the first (neurological) profile were typically aged about 55 years, mostly men, of average educational level, and a small proportion of them had a history of diabetes, cardiovascular disease, or sleep apnea syndrome. At the cognitive level, these patients displayed long-term memory, executive and language disorders. They had more severe anosognosia for their memory difficulties. Nearly all of them reported sleep disorders and emotional apathy. Patients with the second (psychiatric) profile were aged about 45-50 years, and there were equal numbers of men and women. No significant medical antecedents were noted, and the majority of them had had mild or moderate respiratory disease. At the cognitive level, they displayed executive and attentional dysfunctions, which could influence other cognitive domains (e.g., memory recall strategies). At the psychiatric level, they had high scores for depressive symptoms, anxiety, insomnia and stress, and more sporadically exhibited PTSD and dissociative disorders. Our results also indicated the presence of a third (mixed) profile combining the symptoms and clinical characteristics of the two previously described profiles.

# **CONCLUSION**

305

306

307

308

309

310

311

312

313

314

315

This study unambiguously demonstrates the presence of long-term neuropsychological sequelae following SARS-CoV-2 infection, regardless of the severity of the respiratory disease in the acute phase. Some of the cognitive deficits could be explained by psychiatric variables, emphasizing the importance of considering a broad range of psychiatric symptoms. However, not all neuropsychological sequelae could be explained by these variables. The presence of correlations between olfaction, emotion recognition and episodic memory, which share common functional and anatomical substrates, reinforces the hypothesis that the virus targets the CNS (and notably the limbic system). Finally, the data support the notion of different clinical phenotypes, paving the way for clinical guidelines and recommendations for the management of long-term neurological impairment following SARS-CoV-2 infection.

**ACKNOWLEDGEMENTS** 

316

317

318

319

320

321

322

323

324

325

326

The present research was supported by the Swiss National Science Foundation (SNSF) within the framework of the COVID-19 National Research Program (NRP 78; grant no. 407840\_198438, RNP 78) to JAP (PI) and FA (Co-PI). The funders had no role in data collection, discussion of content, preparation of the manuscript, or decision to publish. We would like to thank the patients for contributing their time to this study. **CONFLICT OF INTEREST** The authors report no conflicts of interest.

immunology, 94(2), 182-188.

REFERENCES
Almeria, M., Cejudo, J., Sotoca, J., Deus, J., & Krupinski, J. (2020). Cognitive profile
following COVID-19 infection: Clinical predictors leading to neuropsychological
impairment. Brain, behavior, & immunity-health, 9, 100163.
Ang, YS., Lockwood, P., Apps, M. A., Muhammed, K., & Husain, M. (2017). Distinct
subtypes of apathy revealed by the apathy motivation index. PLoS One, 12(1),
e0169938.
Ashbaugh, A. R., Houle-Johnson, S., Herbert, C., El-Hage, W., & Brunet, A. (2016).
Psychometric validation of the English and French versions of the Posttraumatic Stress
Disorder Checklist for DSM-5 (PCL-5). PloS one, 11(10).
Baig, A. M., Khaleeq, A., Ali, U., & Syeda, H. (2020). Evidence of the COVID-19 virus
targeting the CNS: tissue distribution, host-virus interaction, and proposed
neurotropic mechanisms. ACS chemical neuroscience, 11(7), 995-998.
Bäuerle, A., Teufel, M., Musche, V., Weismüller, B., Kohler, H., Hetkamp, M., Skoda, E
M. (2020). Increased generalized anxiety, depression and distress during the COVID-
19 pandemic: a cross-sectional study in Germany. Journal of Public Health, 42(4),
672-678.
Beck, A. T., Steer, R. A., & Brown, G. K. (1996). Manual for the beck depression inventory-
II. San Antonio, TX: Psychological Corporation, 1, 82.
Bousquet, J., Bullinger, M., Fayol, C., Marquis, P., Valentin, B., & Burtin, B. (1994).
Assessment of quality of life in patients with perennial allergic rhinitis with the French
version of the SF-36 Health Status Questionnaire. Journal of allergy and clinical
1 04/0 100 100

350	Brann, D. H., Tsukahara, T., Weinreb, C., Lipovsek, M., Van den Berge, K., Gong, B.,
351	Fletcher, R. B. (2020). Non-neuronal expression of SARS-CoV-2 entry genes in the
352	olfactory system suggests mechanisms underlying COVID-19-associated anosmia.
353	Science advances, 6(31), eabc5801.
354	Butowt, R., & Bilinska, K. (2020). SARS-CoV-2: olfaction, brain infection, and the urgent
355	need for clinical samples allowing earlier virus detection. ACS chemical neuroscience,
356	11(9), 1200-1203.
357	Carlson, E. B., & Putnam, F. W. (1986). Dissociative experiences scale. <i>Journal of Nervous</i>
358	and Mental Disease, 174(12).
359	Cascella, M., Di Napoli, R., Carbone, D., Cuomo, G. F., Bimonte, S., & Muzio, M. R. (2018).
360	Chemotherapy-related cognitive impairment: mechanisms, clinical features and
361	research perspectives. Recenti progressi in medicina, 109(11), 523-530.
362	De Maria, A., Varese, P., Dentone, C., Barisione, E., & Bassetti, M. (2020). High prevalence
363	of olfactory and taste disorder during SARS-CoV-2 infection in outpatients. Journal of
364	medical virology, 92(11), 2310-2311.
365	Debouverie, M., Pittion-Vouyovitch, S., Louis, S., & Guillemin, F. (2007). Validity of a
366	French version of the fatigue impact scale in multiple sclerosis. Multiple Sclerosis
367	Journal, 13(8), 1026-1032.
368	Doherty, R. W. (1997). The emotional contagion scale: A measure of individual differences.
369	Journal of nonverbal Behavior, 21(2), 131-154.
370	Doty, R. L. (2008). The olfactory vector hypothesis of neurodegenerative disease: is it viable?
371	Annals of Neurology: Official Journal of the American Neurological Association and
372	the Child Neurology Society, 63(1), 7-15.

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

Drozdick, L. W., Raiford, S. E., Wahlstrom, D., & Weiss, L. G. (2018). The Wechsler Adult Intelligence Scale—Fourth Edition and the Wechsler Memory Scale—Fourth Edition. Fajnzylber, J., Regan, J., Coxen, K., Corry, H., Wong, C., Rosenthal, A., . . . Atyeo, C. (2020). SARS-CoV-2 viral load is associated with increased disease severity and mortality. *Nature communications*, 11(1), 1-9. Fodoulian, L., Tuberosa, J., Rossier, D., Boillat, M., Kan, C., Pauli, V., . . . Carleton, A. (2020). Sars-cov-2 receptors and entry genes are expressed in the human olfactory neuroepithelium and brain. *Iscience*, 23(12), 101839. Frei, A., Balzer, C., Gysi, F., Leros, J., Plohmann, A., & Steiger, G. (2016). Kriterien zur Bestimmung des Schweregrades einer neuropsychologischen Störung sowie Zuordnungen zur Funktions-und Arbeitsfähigkeit. Zeitschrift für Neuropsychologie. Goldberg, I. K. (1993). Questions & Answers about Depression and its Treatment: a consultation with a leading psychiatrist: Charles PressPub. Grober, E., & Buschke, H. (1987). Genuine memory deficits in dementia. Dev. Neuropsychol, *3*, 13-36. Gross, J., & John, O. (2003). Emotion regulation questionnaire. *NeuroImage*, 48(10), 9-9. Guedj, Campion, J., Dudouet, P., Kaphan, E., Bregeon, F., Tissot-Dupont, H., ... Ceccaldi, M. (2021). 18 F-FDG brain PET hypometabolism in patients with long COVID. *European journal of nuclear medicine and molecular imaging*, 1-11. Guedi, Million, M., Dudouet, P., Tissot-Dupont, H., Bregeon, F., Cammilleri, S., & Raoult, D. (2020). 18 F-FDG brain PET hypometabolism in post-SARS-CoV-2 infection: substrate for persistent/delayed disorders? European journal of nuclear medicine and molecular imaging, 1-4.

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

Hampshire, A., Trender, W., Chamberlain, S., Jolly, A., Grant, J. E., Patrick, F., . . . Hellyer, P. (2020). Cognitive deficits in people who have recovered from COVID-19 relative to controls: An N= 84,285 online study. *MedRxiv*. Heaton, R. K., Grant, I., & Matthews, C. G. (1991). Comprehensive norms for an expanded Halstead-Reitan battery: demographic corrections, research findings, and clinical applications; with a supplement for the Wechsler Adult Intelligence Scale-Revised (WAIS-R): Psychological Assessment Resources. Husain, M., & Roiser, J. P. (2018). Neuroscience of apathy and anhedonia: a transdiagnostic approach. Nature Reviews Neuroscience, 19(8), 470-484. Iadecola, C., Anrather, J., & Kamel, H. (2020). Effects of COVID-19 on the nervous system. Cell.Johns, M. W. (1991). A new method for measuring daytime sleepiness: the Epworth sleepiness scale. *sleep*, 14(6), 540-545. Kandemirli, S. G., Altundag, A., Yildirim, D., Sanli, D. E. T., & Saatci, O. (2021). Olfactory Bulb MRI and paranasal sinus CT findings in persistent COVID-19 anosmia. *Academic Radiology*, 28(1), 28-35. Kessels, R. P., Van Zandvoort, M. J., Postma, A., Kappelle, L. J., & De Haan, E. H. (2000). The Corsi block-tapping task: standardization and normative data. Applied neuropsychology, 7(4), 252-258. Kohler, O., Krogh, J., Mors, O., & Eriksen Benros, M. (2016). Inflammation in depression and the potential for anti-inflammatory treatment. Current neuropharmacology, 14(7), 732-742. Landis, B. N., Vodicka, J., & Hummel, T. (2010). Olfactory dysfunction following herpetic meningoencephalitis. Journal of neurology, 257(3), 439-443.

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

Lane, R. D. (2008). Neural substrates of implicit and explicit emotional processes: a unifying framework for psychosomatic medicine. Psychosomatic medicine, 70(2), 214-231. Lee, J.-M., & Lee, S. J. (2020). Olfactory and gustatory dysfunction in a COVID-19 patient with ankylosing spondylitis treated with etanercept: case report. Journal of Korean medical science, 35(21). Lehmann, E. L. (2012). Parametric versus nonparametrics: two alternative methodologies. In Selected works of EL Lehmann (pp. 437-445): Springer. Leicht, H., Berwig, M., & Gertz, H.-J. (2010). Anosognosia in Alzheimer's disease: the role of impairment levels in assessment of insight across domains. Journal of the International Neuropsychological Society: JINS, 16(3), 463. Lesage, F.-X., Berjot, S., & Deschamps, F. (2012). Psychometric properties of the French versions of the Perceived Stress Scale. International journal of occupational medicine and environmental health, 25(2), 178-184. Macoir, J., Gauthier, C., Jean, C., & Potvin, O. (2016). BECLA, a new assessment battery for acquired deficits of language: Normative data from Quebec-French healthy younger and older adults. Journal of the neurological sciences, 361, 220-228. Magleby, R., Westblade, L. F., Trzebucki, A., Simon, M. S., Rajan, M., Park, J., . . . Satlin, M. J. (2020). Impact of SARS-CoV-2 viral load on risk of intubation and mortality among hospitalized patients with coronavirus disease 2019. Clinical infectious diseases. Mahieux-Laurent, F., Fabre, C., Galbrun, E., Dubrulle, A., Moroni, C., & Sud, G. d. r. s. l. p. d. C. I.-d.-F. (2009). Validation d'une batterie brève d'évaluation des praxies gestuelles pour consultation Mémoire. Évaluation chez 419 témoins, 127 patients

443	atteints de troubles cognitifs légers et 320 patients atteints d'une démence. Revue
444	neurologique, 165(6-7), 560-567.
445	Mao, L., Jin, H., Wang, M., Hu, Y., Chen, S., He, Q., Wang, D. (2020). Neurologic
446	manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan,
447	China. JAMA neurology, 77(6), 683-690.
448	Mazza, M. G., De Lorenzo, R., Conte, C., Poletti, S., Vai, B., Bollettini, I., Rovere-
449	Querini, P. (2020). Anxiety and depression in COVID-19 survivors: Role of
450	inflammatory and clinical predictors. Brain, behavior, and immunity, 89, 594-600.
451	McCrimmon, R. J., Ryan, C. M., & Frier, B. M. (2012). Diabetes and cognitive dysfunction.
452	The Lancet, 379(9833), 2291-2299.
453	Meinhardt, J., Radke, J., Dittmayer, C., Franz, J., Thomas, C., Mothes, R., Greuel, S.
454	(2021). Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous
455	system entry in individuals with COVID-19. Nature neuroscience, 24(2), 168-175.
456	Merkler, A. E., Parikh, N. S., Mir, S., Gupta, A., Kamel, H., Lin, E., Bruce, S. S. (2020).
457	Risk of ischemic stroke in patients with coronavirus disease 2019 (COVID-19) vs
458	patients with influenza. JAMA neurology, 77(11), 1366-1372.
459	Meyers, J. E., & Meyers, K. R. (1995). Rey Complex Figure Test and recognition trial
460	professional manual: Psychological Assessment Resources.
461	Miyake, A., Friedman, N. P., Emerson, M. J., Witzki, A. H., Howerter, A., & Wager, T. D.
462	(2000). The unity and diversity of executive functions and their contributions to
463	complex "frontal lobe" tasks: A latent variable analysis. Cognitive psychology, 41(1),
464	49-100.
465	Morin, C. M. (1993). Insomnia: psychological assessment and management: Guilford press.

466 Nannoni, S., de Groot, R., Bell, S., & Markus, H. S. (2020). Stroke in COVID-19: a 467 systematic review and meta-analysis. International Journal of Stroke, 468 1747493020972922. 469 Oldfield, R. C. (1971). The assessment and analysis of handedness: the Edinburgh inventory. 470 Neuropsychologia, 9(1), 97-113. 471 Oxley, T. J., Mocco, J., Majidi, S., Kellner, C. P., Shoirah, H., Singh, I. P., . . . Yaeger, K. A. 472 (2020). Large-vessel stroke as a presenting feature of Covid-19 in the young. New 473 England Journal of Medicine, 382(20), e60. 474 Piras, M. R., Magnano, I., Canu, E. D. G., Paulus, K. S., Satta, W. M., Soddu, A., . . . Aiello, 475 I. (2003). Longitudinal study of cognitive dysfunction in multiple sclerosis: 476 neuropsychological, neuroradiological, and neurophysiological findings. Journal of 477 Neurology, Neurosurgery & Psychiatry, 74(7), 878-885. Regina, J., Papadimitriou-Olivgeris, M., Burger, R., Le Pogam, M.-A., Niemi, T., Filippidis, 478 479 P., . . . Kampouri, E. (2020). Epidemiology, risk factors and clinical course of SARS-480 CoV-2 infected patients in a Swiss university hospital: an observational retrospective 481 study. PLoS One, 15(11), e0240781. 482 Rogers, J. P., Chesney, E., Oliver, D., Pollak, T. A., McGuire, P., Fusar-Poli, P., . . . David, 483 A. S. (2020). Psychiatric and neuropsychiatric presentations associated with severe 484 coronavirus infections: a systematic review and meta-analysis with comparison to the 485 COVID-19 pandemic. *The Lancet Psychiatry*. 486 Röhr, S., Müller, F., Jung, F., Apfelbacher, C., Seidler, A., & Riedel-Heller, S. G. (2020). 487 Psychosocial impact of quarantine measures during serious coronavirus outbreaks: a 488 rapid review. Psychiatrische Praxis, 47(4), 179-189.

489	Rosen, H. J., Alcantar, O., Rothlind, J., Sturm, V., Kramer, J. H., Weiner, M., & Miller, B. L.
490	(2010). Neuroanatomical correlates of cognitive self-appraisal in neurodegenerative
491	disease. NeuroImage, 49(4), 3358-3364.
492	Roth, R. M., Gioia, G. A., & Isquith, P. K. (2005). BRIEF-A: Behavior Rating Inventory of
493	Executive Functionadult Version.
494	Roussel, M., & Godefroy, O. (2008). La batterie GREFEX: données normatives. Fonctions
495	exécutives et pathologies neurologiques et psychiatriques, 231-252.
496	Salari, N., Hosseinian-Far, A., Jalali, R., Vaisi-Raygani, A., Rasoulpoor, S., Mohammadi, M.,
497	Khaledi-Paveh, B. (2020). Prevalence of stress, anxiety, depression among the
498	general population during the COVID-19 pandemic: a systematic review and meta-
499	analysis. Globalization and health, 16(1), 1-11.
500	Schlegel, K., Grandjean, D., & Scherer, K. R. (2014). Introducing the Geneva emotion
501	recognition test: an example of Rasch-based test development. Psychological
502	Assessment, 26(2), 666.
503	Schlegel, K., von Gugelberg, H. M., Makowski, L. M., Gubler, D. A., & Troche, S. J. (2021).
504	Emotion Recognition Ability as a Predictor of Well-Being During the COVID-19
505	Pandemic. Social Psychological and Personality Science, 1948550620982851.
506	Soudry, Y., Lemogne, C., Malinvaud, D., Consoli, SM., & Bonfils, P. (2011). Olfactory
507	system and emotion: common substrates. European annals of otorhinolaryngology,
508	head and neck diseases, 128(1), 18-23.
509	Spagnolo, P. A., Manson, J. E., & Joffe, H. (2020). Sex and gender differences in health: what
510	the COVID-19 pandemic can teach us. In: American College of Physicians.

Spielberger, C. D., Gorsuch, R. L., Lushene, R., Vagg, P. R., & Jacobs, G. A. (1993). Manuel
de l'inventaire d'anxiété état-trait forme Y (STAI-Y) [Inventory of state-trait anxiety
manual]. Paris: Editions du Centre de Psychologie Appliquée.
Thomas-Antérion, C., Ribas, C., Honoré-Masson, S., Million, J., & Laurent, B. (2004).
Evaluation de la plainte cognitive de patients Alzheimer, de sujets MCI,
anxiodépressifs et de témoins avec le QPC (Questionnaire de Plainte Cognitive). NPG
Neurologie-Psychiatrie-Gériatrie, 4(20), 30-34.
Tondelli, M., Barbarulo, A. M., Vinceti, G., Vincenzi, C., Chiari, A., Nichelli, P. F., &
Zamboni, G. (2018). Neural correlates of Anosognosia in Alzheimer's disease and
mild cognitive impairment: A multi-method assessment. Frontiers in Behavioral
Neuroscience, 12, 100.
Troyer, E. A., Kohn, J. N., & Hong, S. (2020). Are we facing a crashing wave of
neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential
immunologic mechanisms. Brain, behavior, and immunity.
Vaira, L. A., Hopkins, C., Sandison, A., Manca, A., Machouchas, N., Turilli, D., Cossu,
A. (2020). Olfactory epithelium histopathological findings in long-term coronavirus
disease 2019 related anosmia. The Journal of Laryngology & Otology, 1-5.
Van der Linden, M., Coyette, F., Poitrenaud, J., Kalafat, M., Calicis, F., Wyns, C., & Adam,
S. (2004). II. L'épreuve de rappel libre/rappel indicé à 16 items (RL/RI-16).
van Sonderen, A., Thijs, R. D., Coenders, E. C., Jiskoot, L. C., Sanchez, E., De Bruijn, M. A.,
Smitt, P. A. S. (2016). Anti-LGI1 encephalitis: clinical syndrome and long-term
follow-up. Neurology, 87(14), 1449-1456.

Varatharaj, A., Thomas, N., Ellul, M. A., Davies, N. W., Pollak, T. A., Tenorio, E. L.,
Zandi, M. (2020). Neurological and neuropsychiatric complications of COVID-19 in
153 patients: a UK-wide surveillance study. The Lancet Psychiatry, 7(10), 875-882.
Wang, C., Pan, R., Wan, X., Tan, Y., Xu, L., Ho, C. S., & Ho, R. C. (2020). Immediate
psychological responses and associated factors during the initial stage of the 2019
coronavirus disease (COVID-19) epidemic among the general population in China.
International journal of environmental research and public health, 17(5), 1729.
Warrington, E. K., & James, M. (1991). The visual object and space perception battery.
Wechsler, D. (2008). Wechsler adult intelligence scale-Fourth Edition (WAIS-IV). San
Antonio, TX: NCS Pearson, 22(498), 1.
Wendelken, L. A., & Valcour, V. (2012). Impact of HIV and aging on neuropsychological
function. Journal of neurovirology, 18(4), 256-263.
Woo, M. S., Malsy, J., Pöttgen, J., Seddiq Zai, S., Ufer, F., Hadjilaou, A., Heesen, C.
(2020). Frequent neurocognitive deficits after recovery from mild COVID-19. Brain
Communications, 2(2), fcaa205.
Zimmermann, P., & Fimm, B. (2007). Test for Attentional Performance (TAP), Version 2.1,
Operating Manual. Herzogenrath: PsyTest.

552 SUPPLEMENTARY INDEX 553 Supplementary Index 1. Raw scores (cognitive tests; psychiatric questionnaires 554 included in the principal component analysis). 555 Grober & Buschke (RL/RI 16) - Immediate recall 556 Grober & Buschke (RL/RI 16) - Delayed free recall 557 Grober & Buschke (RL/RI 16) - Delayed total recall 558 MEM III - Spans 559 MEM III - Working verbal memory 560 WAIS IV - Spans 561 WAIS IV - Visuospatial working memory 562 Rey Figure – Copy score 563 Rey Figure - Immediate recall (3') 564 Rey Figure - Delayed recall (20') 565 Stroop (GREFEX)- Interference - Errors 566 Stroop (GREFEX)- Interference/naming - Score 567 TMT B-A (GREFEX) - Score 568 Verbal fluency (GREFEX) - Literal (2') 569 Verbal fluency (GREFEX) - Categorical (2') 570 TAP phasic alertness - Without warning sound - Reaction time 571 TAP phasic alertness - With warning sound - Reaction time 572 TAP phasic alertness - Alertness index 573 TAP sustained attention - Item omissions 574 TAP sustained attention - False alarm 575 TAP divided attention - Audio condition - Reaction time 576 TAP divided attention - Visual condition - Reaction time 577 TAP divided attention - Total omissions 578 TAP divided attention - Total false alarms 579 TAP Incompatibility task - Visual fields \* Hands score 580 BECLA - Semantic image matching 581 BECLA - Semantic word matching

582	BECLA - Object and action image naming
583	BECLA - Word repetition
584	BECLA - Nonword repetition
585	Evaluation of gestural praxis - Symbolic gestures
586	Evaluation of gestural praxis - Action pantomimes
587	Evaluation of gestural praxis - Meaningless gestures
588	VOSP - Fragmented letters
589	VOSP - Object decision
590	VOSP - Number localization
591	VOSP - Cubic counting
592	WAIS IV - Puzzle
593	WAIS IV - Matrix
594	GERT – Emotion recognition task
595	Anosognosia - Memory functions
596	Anosognosia - Executive functions - Working memory
597	Anosognosia - Executive functions - Inhibition
598	Anosognosia - Executive functions - Flexibility